EUVIMEDEUVIMED entdecken
Crossref

LAPIS: A Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Neoadjuvant Pamrevlumab With Chemotherapy for Patients With Locally Advanced Pancreatic Cancer

LAPIS: Eine Phase-III-randomisierte, placebokontrollierte, doppelblinde Studie zu neoadjuvantem Pamrevlumab mit Chemotherapie bei Patient:innen mit lokal fortgeschrittenem Pankreaskarzinom

Vincent Picozzi, Khurum Khan, Pascal Hammel, Michele Reni, Daniel Lin, Woo Jin Lee, Roberto A. Pazo-Cid, Vaibhav Sahai, Andrés Muñoz, Jianjun Liu, Ende Zhao, Teresa Macarulla und 1 weitere

JCO Oncology Advances · 2026-04 · 3 (2)

DOI: 10.1200/oa-26-00026 ↗

Auf einen Blick

In der Phase-III-Studie LAPIS verlängerte Pamrevlumab zusätzlich zur Chemotherapie das Gesamtüberleben bei lokal fortgeschrittenem Pankreaskarzinom nicht. Die Toxizität nahm gegenüber Placebo nicht erkennbar zu.

Fragestellung

Verbessert die Zugabe von Pamrevlumab zur Chemotherapie bei lokal fortgeschrittenem Pankreaskarzinom Wirksamkeit und Sicherheit im Vergleich zu Placebo?

Methode

Phase-III-RCT, doppelblind, placebokontrolliert; 1:1-Randomisierung; Chemotherapie plus Pamrevlumab oder Placebo bis zu 6 Zyklen; primärer Endpunkt OS.

Ergebnisse

284 Patient:innen: 143 in Arm A, 141 in Arm B. Medianes OS 17,3 vs. 17,9 Monate; HR 1,08 (95 %-KI 0,83–1,41), P = .5487. Keine deutliche Zunahme der Toxizität; 1 pamrevlumab-assoziierter Todesfall.

Schlussfolgerung der Autor:innen

LAPIS erreichte den primären Endpunkt nicht. Das Studiendesign mit FDG-PET, definierten chirurgischen Kriterien, unabhängigem Review-Panel und zusammengesetztem Endpunkt erhöhte laut Autoren die Aussagekraft.

Kernaussagen

  • Medianes OS: 17,3 vs. 17,9 Monate
  • HR 1,08 (95 %-KI 0,83–1,41)
  • Keine erkennbare Zunahme der Toxizität

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Advances, 2026-04. Verfasst von Vincent Picozzi und 12 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben.

Auf einen BlickAbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Pamrevlumab demonstrated favorable safety and therapeutic potential in locally advanced pancreatic cancer (LAPC) in phase I/II trials (ClinicalTrials.gov identifiers: NCT01181245 ; NCT02210559 ). LAPIS (phase III; ClinicalTrials.gov identifier: NCT03941093 ) evaluated the efficacy and safety of adding pamrevlumab versus placebo to chemotherapy for patients with LAPC. METHODS Eligible patients (randomly assigned 1:1) received investigator's choice of chemotherapy (gemcitabine plus nab-paclitaxel or folinic acid, fluorouracil, irinotecan, and oxaliplatin per the standard protocol) with either pamrevlumab (35 mg/kg every 2 weeks on days 1 and 15 before chemotherapy; additional dose on day 8 of cycle 1; arm A) or placebo (arm B) for up to six cycles. Patients were assessed for surgical eligibility based on a composite of biomarkers (carbohydrate antigen 19-9, fluorodeoxyglucose positron emission tomography [FDG-PET] imaging, RECIST v1.1 response criteria, and resectability status), guided by an independent surgical review panel. The primary end point was overall survival (OS). Treatment-emergent adverse events were monitored to evaluate safety. RESULTS Of 284 patients, 143 and 141 were randomly assigned to arms A and B, respectively (median [range] age, 65.0 [31-90] years; 53.2% male). The median OS was 17.3 versus 17.9 months for arms A and B, respectively, and the primary end point was not met (hazard ratio [95% CI], 1.08 [0.83 to 1.41]; P = .5487). No appreciable increase in toxicity was noted in the pamrevlumab arm. One pamrevlumab-related death occurred in arm A. CONCLUSION LAPIS did not meet its primary end point in this large, phase III trial featuring a design including FDG-PET imaging for response assessment, defined surgical eligibility criteria, an independent surgical review panel, and a composite event-free survival end point, collectively enhancing assessment rigor and clinical applicability and potentially establishing future standards for LAPC trials.

Zitieren

APA

Picozzi, V., Khan, K., Hammel, P., Reni, M., Lin, D., Lee, W. J., Pazo-Cid, R. A., Sahai, V., Muñoz, A., Liu, J., Zhao, E., Macarulla, T., & Carrier, E. (2026). LAPIS: A Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Neoadjuvant Pamrevlumab With Chemotherapy for Patients With Locally Advanced Pancreatic Cancer. JCO Oncology Advances, 3(2). https://doi.org/10.1200/oa-26-00026

Vancouver

Picozzi V, Khan K, Hammel P, Reni M, Lin D, Lee WJ, et al. LAPIS: A Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Neoadjuvant Pamrevlumab With Chemotherapy for Patients With Locally Advanced Pancreatic Cancer. JCO Oncology Advances. 2026;3(2). doi:10.1200/oa-26-00026

BibTeX
@article{Picozzi2026,
  author = {Picozzi, Vincent and Khan, Khurum and Hammel, Pascal and Reni, Michele and Lin, Daniel and Lee, Woo Jin and Pazo-Cid, Roberto A. and Sahai, Vaibhav and Muñoz, Andrés and Liu, Jianjun and Zhao, Ende and Macarulla, Teresa and Carrier, Ewa},
  title = {LAPIS: A Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Neoadjuvant Pamrevlumab With Chemotherapy for Patients With Locally Advanced Pancreatic Cancer},
  journal = {JCO Oncology Advances},
  year = {2026},
  volume = {3},
  number = {2},
  doi = {10.1200/oa-26-00026}
}
Kostenlos starten →